What Is Absent End-Diastolic Flow in Pregnancy?

Absent end-diastolic flow (AEDF) is a Doppler ultrasound finding in which blood flow through the umbilical artery drops to zero during the relaxation phase of each fetal heartbeat. In a healthy pregnancy, blood continues moving forward through the umbilical cord even between heartbeats, pushed along by low resistance in a well-developed placenta. When that forward flow disappears entirely during diastole, it signals that something has gone wrong with how the placenta is built or functioning. The finding is strongly associated with fetal growth restriction and carries real risks, but how those risks play out depends on whether the absent flow is constant or comes and goes, how far along the pregnancy is, and how the fetus is compensating.

What Is Happening Inside the Placenta

The placenta is essentially a dense network of tiny blood vessels where maternal and fetal blood come close enough to exchange oxygen and nutrients without mixing directly. When this vascular network develops abnormally or becomes damaged, resistance to blood flow increases. At some point, resistance climbs high enough that the fetal heart can no longer push blood forward during its resting phase between beats. That is the moment end-diastolic flow disappears.

Placental examinations after delivery tell a consistent story. Compared to growth-restricted pregnancies where some forward flow remains, placentas from AEDF pregnancies show significantly more blood vessels with thickened walls and blocked-off lumens in the fetal stem vessels, the large channels that branch out into the placental tissue.¹ A separate study found that these placentas also had more avascular villi (clusters of tissue that have lost their blood supply entirely), chronic inflammation in the decidua (the maternal side of the placenta), and hardening of decidual arteries.² In short, the placenta in AEDF pregnancies is not just underperforming; its internal plumbing is structurally compromised on both the fetal and maternal sides.

How Doctors Detect It and Why Technique Matters

AEDF is identified using Doppler ultrasound, the same technology that lets you hear the fetal heartbeat during a routine prenatal visit. During a Doppler exam of the umbilical artery, the clinician looks at the waveform pattern produced by blood flowing through the cord. In a normal tracing, flow never drops to zero. In AEDF, the waveform hits the baseline or below it during diastole. Reversed end-diastolic flow (REDF), a more severe finding, shows blood actually moving backward during diastole.

One underappreciated factor is that fetal activity can change what the waveform looks like. Fetal breathing movements create irregular patterns in the Doppler tracing, and body movements cause heart rate accelerations that alter the shape of the waveform.³ A measurement taken during a bout of fetal hiccups or vigorous kicking might look abnormal when the underlying flow is actually fine, or it might mask a genuine problem. This is why most protocols call for repeated measurements during periods of fetal quiet, and why a single isolated reading rarely triggers immediate action.

The Spectrum from Reduced to Absent to Reversed

AEDF is not an all-or-nothing event. It sits on a spectrum of worsening placental dysfunction. As placental resistance climbs, the Doppler waveform first shows reduced end-diastolic flow, meaning blood is still moving forward between beats but less vigorously than expected. If the problem progresses, diastolic flow disappears entirely (AEDF). In the most severe cases, it reverses direction (REDF), meaning blood is actually flowing backward through the umbilical artery during diastole.⁴

This progression does not always march relentlessly forward. In a small number of cases, AEDF can spontaneously improve around the 27th week of pregnancy and return to normal, though there is currently no reliable way to predict which pregnancies will do this.⁴ Compared to pregnancies where reduced (but still present) end-diastolic flow is the worst finding, pregnancies with absent or reversed flow have higher rates of low birth weight, worse newborn scores, more emergency cesarean deliveries, more intensive care admissions, and greater perinatal mortality.

How the Fetus Adapts to Reduced Oxygen

When placental function declines and less oxygen reaches the fetus, the fetal circulatory system does not simply continue as usual. It actively redirects blood toward the most critical organs, particularly the brain and heart, and away from less immediately essential areas like the gut, kidneys, and limbs. This process is often called “brain sparing.”

Brain sparing is detected by measuring blood flow in the middle cerebral artery, a major vessel supplying the fetal brain. When the fetus is struggling for oxygen, resistance in this artery drops, allowing more blood to reach the brain. Clinicians track this by comparing middle cerebral artery flow to umbilical artery flow using a ratio called the cerebroplacental ratio, or CPR.⁵ A low CPR suggests the fetus is compensating for poor placental flow by funneling blood preferentially to the brain. This is an adaptive response and, in a sense, a sign that the fetal cardiovascular system is working, but it also signals that the fetus is under significant stress.

Brain sparing has limits. When the redistribution is incomplete or insufficient, the fetal heart rate pattern starts to deteriorate. In fetuses with AEDF, reduced heart rate variability developed in all cases where redistribution had progressed beyond just the middle cerebral artery to also involve the aorta. These fetuses eventually showed repeated heart rate decelerations that prompted delivery.⁶ In other words, brain sparing buys time, but once the fetus’s cardiovascular reserves are exhausted, the situation can deteriorate quickly.

Intermittent Versus Persistent Absent Flow

Not all cases of AEDF behave the same way. In some pregnancies, end-diastolic flow disappears on one scan but reappears on the next, a pattern described as intermittent AEDF. In others, once the flow disappears, it stays gone (persistent AEDF). This distinction carries practical weight.

A study comparing these two groups found that the average time from diagnosis to delivery was roughly twice as long in the intermittent group (about 16 days) compared to the persistent group (about 8 days). Babies in the intermittent group tended to reach a later gestational age at delivery and had better newborn scores. All four stillbirths in the study occurred in the persistent group, though the difference did not reach statistical significance given the small number of deaths.⁷ These findings suggest that intermittent AEDF may represent an earlier or less severe stage of placental failure, one where close outpatient surveillance can be reasonable, whereas persistent AEDF warrants more intensive inpatient monitoring.

Monitoring After Diagnosis

Once AEDF is confirmed, the clinical team shifts into a surveillance mode aimed at determining how the fetus is coping and how quickly the situation is changing. Umbilical artery Doppler is the starting point, but it is not the only tool. Clinicians also look at venous flow patterns, particularly in the ductus venosus, a small vessel in the fetal liver that provides a window into how well the fetal heart is handling the increased workload.

Abnormal ductus venosus Doppler findings tend to appear after umbilical artery changes and can signal further deterioration. However, these readings are not perfectly stable. One study following fetuses with absent or reversed end-diastolic flow over time found that while ductus venosus Doppler could detect worsening, the readings showed striking short-term variability, meaning a single snapshot could be misleading.⁸ There is also a measurable time lag between when AEDF first appears and when the ductus venosus readings become clearly abnormal, which matters for deciding how urgently delivery needs to happen.⁹

Fetal heart rate monitoring adds another layer. Computerized cardiotocography can pick up declining heart rate variability and the development of decelerations, both of which suggest the fetus is running out of compensatory reserves.⁶ Together, these tools help clinicians walk the tightrope between delivering too early (exposing the baby to severe prematurity) and delivering too late (risking stillbirth or irreversible organ damage).

What Corticosteroids Do (and Do Not Do)

When preterm delivery looks likely, antenatal corticosteroids are given to the mother to speed up fetal lung maturation. In AEDF pregnancies, these steroids have an interesting side effect on the Doppler readings themselves. Studies have reported that betamethasone can temporarily restore end-diastolic flow in a significant proportion of cases. One study found that end-diastolic flow returned in up to 70% of fetuses after steroid administration, though the babies who experienced this restoration were less acidotic at birth but did not have significantly better hospital outcomes overall.¹⁰

Another study found a somewhat lower rate of temporary restoration, with flow returning in about 45% of pregnancies. That study also found that while middle cerebral artery blood flow increased (suggesting improved brain perfusion), there was no significant change in umbilical artery or ductus venosus patterns overall.¹¹ A review of the broader evidence noted that some researchers reported delayed deterioration of fetal heart rate tracings and improved perinatal outcomes after steroids in this population, though the evidence remains mixed.¹²

The key takeaway is that the temporary return of end-diastolic flow after steroids should not be mistaken for a cure. The underlying placental disease has not resolved. The main purpose of corticosteroids remains lung maturation for a preterm delivery that is likely coming soon, and any improvement in Doppler readings is a secondary and transient effect.

Risks for the Newborn

The fetal blood flow redistribution that protects the brain before delivery has consequences for the organs that got shortchanged, particularly the gut. Necrotizing enterocolitis (NEC), a serious and sometimes fatal bowel condition in premature infants, has a well-documented association with prenatal AEDF. One matched study found that over half (53%) of morphologically normal fetuses who had AEDF developed NEC after birth, compared to just 6% of matched controls who had normal umbilical artery flow. This association held even after accounting for the degree of growth restriction, prematurity, and birth asphyxia.¹³

However, the picture is not identical in every population. A study specifically looking at infants born to women with severe early-onset preeclampsia and AEDF concluded that although these fetuses did redistribute blood away from the gut, the intestinal compromise was not severe enough on its own to cause NEC in that particular group.¹⁴ This discrepancy likely reflects the fact that NEC has multiple contributing causes (infection, feeding practices, extreme prematurity) and that prenatal flow redistribution may be one factor among several rather than a sole trigger.

Beyond the gut, neurodevelopmental outcomes are a serious concern. Very preterm infants born after early fetal growth restriction with AEDF scored lower on developmental assessments at both 12 and 24 months of age compared to preterm infants of similar gestational age who were born appropriate-for-size. The gap was particularly pronounced in the performance domain, which includes tasks involving hand-eye coordination and problem-solving, and this difference persisted through the second year of life.¹⁵ Long-term neurological impairment is recognized as a broader risk in pregnancies complicated by absent or reversed end-diastolic flow.⁴

When and How Delivery Is Timed

There is no single gestational age at which all AEDF pregnancies are delivered. The decision is a balancing act between the risks of continued exposure to a failing placenta and the risks of extreme prematurity. The clinical picture at the time of diagnosis, how far along the pregnancy is, whether the AEDF is intermittent or persistent, and how the fetus is responding all factor into the timing.

In many centers, persistent AEDF in a viable fetus prompts hospital admission and daily (or more frequent) monitoring. Delivery is triggered by deteriorating venous Doppler patterns, declining heart rate variability, repeated decelerations on cardiotocography, or reaching a gestational age threshold at which the risks of staying pregnant outweigh the risks of prematurity. For very early presentations, before the threshold of viability, the management conversation becomes more about whether and when to intervene at all, which involves difficult discussions about prognosis and parental values.

The data on intermittent versus persistent AEDF has started to influence management. Since the intermittent pattern appears to carry a better prognosis and allows more time before delivery, some clinicians are now considering outpatient monitoring for these cases rather than immediate hospitalization.⁷ Delivery is almost always by cesarean section, given that these fetuses are already compromised and may not tolerate the stress of labor.

Investigational Therapies

Because the fundamental problem in AEDF is poor placental blood flow, researchers have explored whether vasodilator drugs could open up the placental vessels enough to improve oxygen delivery. Sildenafil citrate, the drug better known commercially for erectile dysfunction, works by relaxing smooth muscle in blood vessel walls. Several small studies and case reports have tested it in pregnancies complicated by fetal growth restriction and AEDF.

In one study, sildenafil was given to women with growth-restricted fetuses in an attempt to improve blood flow through the uterine and umbilical arteries. The researchers reported improved Doppler readings after treatment.¹⁶ A case report described similar improvements in a pregnancy with early-onset fetal growth restriction and AEDF, with Doppler parameters improving and the pregnancy achieving a favorable outcome.¹⁷

These results are preliminary and should be interpreted cautiously. A large international trial (the STRIDER consortium) was stopped early in some countries due to safety concerns, including an increase in a serious neonatal lung condition in the treatment group. Sildenafil for fetal growth restriction remains experimental and is not part of standard clinical care. The early positive Doppler findings from small studies have not reliably translated into better survival or fewer complications in larger trials.

What Happens in the Next Pregnancy

For women who have experienced AEDF in one pregnancy, the question of recurrence looms large. The available evidence is reassuring, if limited. One study followed women who had AEDF in a prior pregnancy. The index pregnancies were severe: perinatal mortality was 56%, growth restriction occurred in nearly all cases, and all babies were born preterm. In their subsequent pregnancies, however, about three quarters were uncomplicated. No perinatal deaths occurred, and none of the babies were delivered before 32 weeks. AEDF recurred in only two of the subsequent pregnancies, and both of those were complicated.¹⁸

The relatively low recurrence rate likely reflects the fact that many AEDF cases are linked to placenta-specific problems rather than permanent maternal conditions. Each pregnancy builds a new placenta, and the odds that the same severe vascular abnormalities will develop again are not negligible but are far from certain. Women with underlying conditions that predispose to poor placentation, such as antiphospholipid syndrome or chronic hypertension, face higher recurrence risk and typically receive additional surveillance and sometimes preventive treatments like low-dose aspirin in subsequent pregnancies.

Conditions That Often Travel with AEDF

AEDF rarely occurs in an otherwise unremarkable pregnancy. The most common association is fetal growth restriction, where the fetus is measuring significantly smaller than expected. Preeclampsia, particularly the severe early-onset form, is another frequent companion. Many of the studies that have defined our understanding of AEDF are drawn specifically from populations of women with early preeclampsia and growth-restricted fetuses.¹⁴

Other associations include thrombophilias (conditions that increase the tendency of blood to clot), chronic kidney disease, autoimmune conditions, and pregnancies affected by certain chromosomal abnormalities. In some cases, AEDF appears without any identifiable maternal risk factor, pointing to a primary placental problem. Regardless of the underlying cause, the finding itself tells clinicians the same thing: the placenta is failing to provide adequate blood flow, and the pregnancy needs closer attention.

1
PubMed. Placental pathology of absent and reversed end-diastolic flow in growth-restricted fetuses
2
Journal of Pathology and Translational Medicine. Pathologic Differences between Placentas from Intrauterine Growth Restriction Pregnancies with and without Absent or Reversed End Diastolic Velocity of Umbilical Arteries
3
Early Human Development. The umbilical artery blood flow velocity waveform in relation to fetal breathing movements, fetal heart rate and fetal behavioural states in normal pregnancy at 37 to 39 weeks
4
PubMed Central. Doppler Ultrasound of the Umbilical Artery: Clinical Application
5
PubMed Central. Patterns of Brain Sparing in a Fetal Growth Restriction Cohort
6
PubMed. Central and peripheral hemodynamic changes in fetuses with absent end-diastolic velocity in umbilical artery: correlation with computerized fetal heart rate pattern
7
PubMed Central. Clinical significance of intermittently absent end-diastolic flow of the fetal umbilical artery on perinatal and neonatal outcomes
8
PubMed. Arterial and ductus venosus Doppler in fetuses with absent or reverse end-diastolic flow in the umbilical artery: longitudinal analysis
9
PubMed. Ductus venosus Doppler and the postnatal outcomes of growth restricted fetuses with absent end-diastolic blood flow in the umbilical arteries
10
Pediatrics. Infant Outcome After Antenatal Steroids in Preterm Pregnancies with Absent Umbilical End-Diastolic Flow
11
Acta Obstetricia et Gynecologica Scandinavica. Effect of antenatal corticosteroid administration on Doppler flow velocity parameters in pregnancies with absent or reverse end‐diastolic flow in the umbilical artery
12
PubMed Central. Antenatal Corticosteroids in Early and Late Fetal Growth Restriction
13
PubMed Central. Absent or reversed end diastolic flow velocity in the umbilical artery and necrotising enterocolitis
14
PubMed. Necrotizing enterocolitis in infants born to women with severe early preeclampsia and absent end-diastolic umbilical artery doppler flow velocity waveforms
15
PubMed Central. Neurodevelopmental outcomes of very preterm infants born following early foetal growth restriction with absent end-diastolic umbilical flow
16
PubMed Central. Sildenafil Citrate in Fetal Growth Restriction
17
International Journal of Reproduction, Contraception, Obstetrics and Gynecology. Sildenafil citrate therapy in absent end diastolic flow in umbilical artery in an early onset fetal growth restriction (FGR) fetus
18
PubMed. Absent end-diastolic flow velocity waveforms in the umbilical artery–the subsequent pregnancy